A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase‐2 in idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Selective silencing of the cyclooxygenase‐2 (COX‐2) gene with the loss of the antifibrotic mediator prostaglandin E 2 contributes to the fibrotic process in idiopathic pulmonary fibrosis (IPF). This study explored the role of G9a‐ and enhancer of zeste homolog 2 (EZH2)‐mediated methylation of histone H3 lysine 9 (H3K9me3) and histone H3 lysine 27 (H3K27me3) in COX‐2 silencing in IPF. Chromatin immunoprecipitation (ChIP) and re‐ChIP assays demonstrated marked increases in H3K9me3, H3K27me3, and DNA methylation, together with their respective modifying enzymes G9a, EZH2, and DNA methyltransferases (Dnmts) and respective binding proteins heterochromatin protein 1 (HP1), polycomb protein complex 1 (PRC1) and methyl CpG binding protein 2 (MeCP2), at the COX‐2 promoter in lung fibroblasts from patients with IPF (F‐IPFs) compared with fibroblasts from nonfibrotic lungs. HP1, EZH2, and MeCP2 in turn were associated with additional repressive chromatin modifiers in F‐IPFs. G9a and EZH2 inhibitors and small interfering RNAs and the Dnmt1 inhibitor markedly reduced H3K9me3 (49–79%), H3K27me3 (44–81%), and DNA methylation (61–97%) at the COX‐2 promoter. These reductions were correlated with increased histone H3 and H4 acetylation, resulting in COX‐2 mRNA and protein reexpression in F‐IPFs. Our results support a central role for G9a‐ and EZH2‐mediated histone hypermethylation and a model of bidirectional, mutually reinforcing, and interdependent crosstalk between histone hypermethylation and DNA methylation in COX‐2 epigenetic silencing in IPF.—Coward, W. R., Feghali‐Bostwick, C. A., Jenkins, G., Knox, A. J., Pang, L. A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase‐2 in idiopathic pulmonary fibrosis. FASEB J . 28, 3183–3196 (2014). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins
Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., & Jenuwein, T. (2001) · Nature · doi:10.1038/35065132 · Cited by 2,868 · cited 5×
“1D, F), but not the HMT SUV39H1, also responsible for H3K9me3 (Fig.”
BackgroundInfluentialThe Polycomb group protein EZH2 directly controls DNA methylation
Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596 · cited 11×
“2E) and that EED was associated with NCoR, CoREST, and mSin3a at the COX-2 promoter in F-IPFs (Fig.”
BackgroundInfluentialSchlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J., Eden, E., Yakhini, Z., Ben-Shushan, E., Reubinoff, B. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1950 · Cited by 1,226 · cited 2×
“There are reports indicating that EZH2 directly interacts with Dnmts and is necessary for de novo DNA methylation for PRC2 target gene promoters (6, 7).”
BackgroundReversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase
Kubicek, S., O'Sullivan, R. J., August, E. M., Hickey, E. R., Zhang, Q., Teodoro, M. L., Rea, S., Mechtler, K., Kowalski, J. A., Homon, C. A., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.01.017 · Cited by 859
Iguchi-Ariga, S. M., & Schaffner, W. (1989) · Genes & Development · doi:10.1101/gad.3.5.612 · Cited by 559 · cited 1×
“Direct inhibition of transcription may be through blocking the binding of transcription factors to promoters containing methylated CpG sites (9), whereas indirect repression may involve proteins such as methyl CpG binding protein 2 (MeCP2) that specifically bind to methylated DNA via a methyl”
BackgroundChen, M.-W., Hua, K.-T., Kao, H.-J., Chi, C.-C., Wei, L.-H., Johansson, G., Shiah, S.-G., Chen, P.-S., Jeng, Y.-M., Cheng, T.-Y., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0833 · Cited by 369 · cited 2×
“expression in lung cancer cells (31) and that G9a”
Background
Cited by
Martinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J. J., Taniguchi, H., & Wells, A. U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.74 · Cited by 1,388
Epigenetics in health and disease
Zhang, L., Lu, Q., & Chang, C. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3449-2_1 · Cited by 689
Matrix Metalloproteinases as Therapeutic Targets for Idiopathic Pulmonary Fibrosis
Craig, V. J., Zhang, L., Hagood, J. S., & Owen, C. A. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0020tr · Cited by 507
Allen, R. J., Porte, J., Braybrooke, R., Flores, C., Fingerlin, T. E., Oldham, J. M., Guillen-Guio, B., Ma, S.-F., Okamoto, T., John, A. E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30387-9 · Cited by 297
Lung cancer in patients with idiopathic pulmonary fibrosis
Karampitsakos, T., Tzilas, V., Tringidou, R., Steiropoulos, P., Aidinis, V., Papiris, S. A., Bouros, D., & Tzouvelekis, A. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.03.016 · Cited by 171
“p21 waf1/cip1 and Fas has been established both in IPF and lung cancer (99-102).”
Background
Metadata
- Authors
- Coward, W. R., Feghali‐Bostwick, C. A., Jenkins, G., Knox, A. J., & Pang, L.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2014-03-20
- Volume
- 28
- Issue
- 7
- Pages
- 3183-3196
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2088711557
- Cited by
- 117
- References
- 7
- FWCI
- 8.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.